SE0102639D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0102639D0
SE0102639D0 SE0102639A SE0102639A SE0102639D0 SE 0102639 D0 SE0102639 D0 SE 0102639D0 SE 0102639 A SE0102639 A SE 0102639A SE 0102639 A SE0102639 A SE 0102639A SE 0102639 D0 SE0102639 D0 SE 0102639D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
prophylaxis
pain
Prior art date
Application number
SE0102639A
Other languages
English (en)
Swedish (sv)
Inventor
David Cheshire
Stephen Connolly
Antonio Mete
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102639A priority Critical patent/SE0102639D0/xx
Publication of SE0102639D0 publication Critical patent/SE0102639D0/xx
Priority to EP02751942A priority patent/EP1421067A1/fr
Priority to US10/484,960 priority patent/US7119109B2/en
Priority to PCT/SE2002/001415 priority patent/WO2003011831A1/fr
Priority to JP2003517023A priority patent/JP2004538313A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0102639A 2001-07-31 2001-07-31 Novel compounds SE0102639D0 (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE0102639A SE0102639D0 (sv) 2001-07-31 2001-07-31 Novel compounds
EP02751942A EP1421067A1 (fr) 2001-07-31 2002-07-26 Derives d'heteroarylheteroalkylamine et leur utilisation comme inhibiteurs de la synthase d'oxyde nitrique
US10/484,960 US7119109B2 (en) 2001-07-31 2002-07-26 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
PCT/SE2002/001415 WO2003011831A1 (fr) 2001-07-31 2002-07-26 Derives d'heteroarylheteroalkylamine et leur utilisation comme inhibiteurs de la synthase d'oxyde nitrique
JP2003517023A JP2004538313A (ja) 2001-07-31 2002-07-26 ヘテロアリールへテロアルキルアミン誘導体および一酸化窒素シンターゼの阻害剤としてのそれらの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102639A SE0102639D0 (sv) 2001-07-31 2001-07-31 Novel compounds

Publications (1)

Publication Number Publication Date
SE0102639D0 true SE0102639D0 (sv) 2001-07-31

Family

ID=20284964

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102639A SE0102639D0 (sv) 2001-07-31 2001-07-31 Novel compounds

Country Status (5)

Country Link
US (1) US7119109B2 (fr)
EP (1) EP1421067A1 (fr)
JP (1) JP2004538313A (fr)
SE (1) SE0102639D0 (fr)
WO (1) WO2003011831A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417064B2 (en) 2002-11-05 2008-08-26 Eli Lilly And Company 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
JP2008510776A (ja) * 2004-08-26 2008-04-10 ノイロサーチ アクティーゼルスカブ モノアミン神経伝達物質再取込み阻害剤としての新規な置換ヘテロアリールオキシアルキルアミン及びそれらの使用
EP1757290A1 (fr) 2005-08-16 2007-02-28 Zentaris GmbH Derivés de triazole comme ligands du recepteur de l'hormone de croissance
ES2553891T3 (es) * 2007-06-04 2015-12-14 Intra-Cellular Therapies, Inc. Derivados de piridina como moduladores NET/SERT
EP2431035A1 (fr) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Nouveaux dérivés de triazole avec activité de récepteur améliorée et propriétés de biodisponibilité en tant qu'antagonistes de ghréline de récepteurs de secrétagogue d'hormone de croissance
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535328A (en) * 1967-09-01 1970-10-20 Exxon Research Engineering Co Certain substituted aminothioethoxy pyridines
JPS5144934B1 (fr) * 1969-12-09 1976-12-01
GB2060622B (en) * 1979-09-14 1983-05-25 Wyeth John & Brother Ltd 3-aryl-3-aryloxyalkylamines
DE3138550A1 (de) * 1981-09-28 1983-04-07 Boehringer Ingelheim KG, 6507 Ingelheim Substituierte 2-phenyl-2-(pyridyloxy)-ethylamine und isostere verbindungen, verfahren zu ihrer herstellung und verwendung
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
EP0571685A1 (fr) * 1992-05-27 1993-12-01 Novo Nordisk A/S Aryloxyhétéroaryle propylamines, leur préparation et leur utilisation
ES2169102T3 (es) * 1994-10-14 2002-07-01 Merck Patent Gmbh (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano como agente activo sobre el sistema nervioso central.
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP1421067A1 (fr) 2004-05-26
US20040220234A1 (en) 2004-11-04
WO2003011831A1 (fr) 2003-02-13
JP2004538313A (ja) 2004-12-24
US7119109B2 (en) 2006-10-10

Similar Documents

Publication Publication Date Title
MXPA03010142A (es) Nuevos derivados de arilheteroalquilamina.
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
SE9803518D0 (sv) Novel compounds
ATE248837T1 (de) Chinuclidin-acrylamide
GB0004153D0 (en) Novel use
SE0302324D0 (sv) Novel compounds
ATE331711T1 (de) Entzündungshemmende 3-arylthio-3- thiazolylalkylamine
DE60205455T2 (de) Naphthyridinderivate
SE0302323D0 (sv) Novel compounds
SE9701304D0 (sv) Compounds
AU1182702A (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
SE9803773D0 (sv) Compounds
SE0302756D0 (sv) Novel Compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
SE0102641D0 (sv) Novel compounds
SE0102639D0 (sv) Novel compounds
GB0004152D0 (en) Novel compounds
SE0103325D0 (sv) Novel compounds
SE0102640D0 (sv) Novel compounds
SE0202280D0 (sv) Novel compounds
SE0300907D0 (sv) Novel compounds
SE9901530D0 (sv) Novel compounds
NO20042729L (no) Heksasykliske forbindelser
SE0202279D0 (sv) Novel comppounds
SE0300906D0 (sv) Novel compounds